New evidence on the association of shortened sleep time and obstructive sleep apnea with sleepiness and cardiometabolic risk factors

April 01, 2019

Glenview, IL, April 1, 2019 - A new study appearing in the journal CHEST®, published by Elsevier, may change the way we think about sleep disorders. In this study led by Dr. Luciano F. Drager, obstructive sleep apnea (OSA) and short sleep duration (SSD) were compared with excessive daytime sleepiness; anxiety/depressive symptoms; and several cardiometabolic risk factors including obesity, hypertension, diabetes and dyslipidemia. Using a large sample of adults, investigators found that SSD, but not OSA, was independently associated with daytime sleepiness. In contrast, OSA, but not SSD, was independently associated with obesity, hypertension, and dyslipidemia. Neither was independently associated with anxiety or depression.

Tracking OSA and SSD in the same investigation allowed researchers to compare the potential consequences of the two most common sleep disorders, and the results of this study challenge some traditional beliefs. "Our findings suggest potential distinct clinical impacts of OSA and SSD," explained Luciano F. Drager, MD, PhD, of the Center of Clinical and Epidemiologic Research (CPCE); Hypertension Unit, Heart Institute (InCor); and Hypertension Unit, Renal Division, of the University of Sao Paulo, Sao Paulo, Brazil. "The potential impact on patient care is that our results underscore the need to advance our knowledge of OSA and SSD determination to avoid the 'one-size-fits-all' approach and instead tailor personalized preventive, diagnostic, prognostic, and therapeutic strategies to our patients."

Data came from close to 2,100 participants from the cross-sectional Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), a long-term study of Brazilian civil servants (ages 35 to 74 years) that aims to help investigators learn about the development and progression of clinical and subclinical chronic diseases. Participants were not referred for sleep studies and anyone being treated for OSA, receiving sleep-interfering medications, or engaged in nocturnal or shift work was excluded.

More sleep disorders were identified in patients studied than anticipated, including almost one third with OSA. More than one quarter of participants had SSD, meaning that they slept on average less than six hours a night. A significant overlap of about 11 percent of the patients manifested both OSA and SSD, although no interaction was found between OSA and SSD.

The study reported some findings that are contrary to traditional thinking. For instance, because this study measured sleep duration objectively with a device (wrist actigraphy over a seven-day period), rather than relying on patient self-reporting, the investigators found more people with inappropriate sleep durations than commonly thought. "In this study, only one quarter of participants slept seven to eight hours on average, the most highly recommended sleep duration for middle-aged adults," said Dr. Drager. While individuals with SSD were more likely to report excessive sleepiness during the daytime, SSD was not associated with obesity, hypertension, or dyslipidemia.

Another surprising finding was that OSA was not associated with excessive daytime sleepiness, even if OSA was severe. However, OSA was, associated with obesity, hypertension, and dyslipidemia, but not with anxiety or depression. In subgroup analysis, obesity was associated with all levels of OSA severity, but only severe OSA was associated with hypertension. "Our findings do not mean that OSA never causes sleepiness, but in clinical practice a significant proportion of patients with OSA are asymptomatic or minimally symptomatic," noted Dr. Drager.

Dr. Drager suggests that in previous studies any positive associations found between SSD and cardiometabolic risk factors could have been due to "occult" (non-apparent) OSA. "The additional lack of association of SSD with obesity, dyslipidemia, and diabetes in our large cohort reinforces the potential need to reappraise the evidence on subjective SSD and cardiometabolic risk factors," commented Dr. Drager.
-end-


Elsevier

Related Obesity Articles from Brightsurf:

11 years of data add to the evidence for using testosterone therapy to treat obesity, including as an alternative to obesity surgery
New research covering 11 years of data presented at this year's European and International Congress on Obesity (ECOICO 2020) show that, in obese men suffering from hypogonadism (low testosterone), treatment with testosterone injections lowers their weight and improves a wide range of other metabolic parameters.

Overlap between immunology of COVID-19 and obesity could explain the increased risk of death in people living with obesity, and also older patients
Data presented in a special COVID-19 session at the European and International Congress on Obesity (ECOICO 2020) suggests that there are overlaps between the immunological disturbances found in both COVID-19 disease and patients with obesity, which could explain the increased disease severity and mortality risk faced by obese patients, and also elderly patients, who are infected by the SARS-CoV-2 virus that causes COVID-19 disease.

New obesity guideline: Address root causes as foundation of obesity management
besity management should focus on outcomes that patients consider to be important, not weight loss alone, and include a holistic approach that addresses the root causes of obesity, according to a new clinical practice guideline published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.191707.

Changing the debate around obesity
The UK's National Health Service (NHS) needs to do more to address the ingrained stigma and discrimination faced by people with obesity, says a leading health psychologist.

Study links longer exposure to obesity and earlier development of obesity to increased risk of type 2 diabetes
Cumulative exposure to obesity could be at least as important as actually being obese in terms of risk of developing type 2 diabetes (T2D), concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).

How much do obesity and addictions overlap?
A large analysis of personality studies has found that people with obesity behave somewhat like people with addictions to alcohol or drugs.

Should obesity be recognized as a disease?
With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognize it as a disease?

Is obesity associated with risk of pediatric MS?
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.

Women with obesity prior to conception are more likely to have children with obesity
A systematic review and meta-analysis identified significantly increased odds of child obesity when mothers have obesity before conception, according to a study published June 11, 2019 in the open-access journal PLOS Medicine by Nicola Heslehurst of Newcastle University in the UK, and colleagues.

Obesity medicine association announces major updates to its adult obesity algorithm
The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.

Read More: Obesity News and Obesity Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.